ArticleEndocrine2025
Efficacy assessment of repeat iodine-131 treatment in patients with papillary thyroid carcinoma assessed as biochemical incomplete response.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough most patients with Papillary Thyroid Carcinoma (PTC) have a favorable prognosis, some continue to have elevated serum Thyroglobulin (Tg) levels after surgery and ¹³¹I treatment, classified as a Biochemical Incomplete Response (BIR). According to the 2015 American Thyroid Association (ATA) guidelines, 20% of these patients will develop a Structural Incomplete Response (SIR). Doctors often recommend ¹³¹I retreatment without imaging evidence, hoping for benefits. However, the effectiveness of this treatment strategy is still not supported by evidence. The aim of this study is to explore the potential benefits by comparing Tg levels and their changes in patients who were retreated with
methodsThis retrospective study collected clinical data from patients with PTC who underwent ¹³¹I therapy after surgery at two medical centers. All of them were evaluated for Biochemical Incomplete Response (BIR) after initial treatment. Based on whether they received ¹³¹I retreatment, they were divided into two groups: the retreatment group and the no-retreatment group. Our primary outcome measures included basic clinical data, suppressed Tg, change in Tg levels, and DRS stratification at the last follow-up. The potential benefits of ¹³¹I retreatment were analyzed by comparing the changes in Tg levels and the DRS distribution at the end of follow-up between the two groups.
resultsPatients with PTC assessed for BIR after initial therapy showed a greater reduction in Tg at short-term follow-up after ¹³¹I retreatment compared to the no retreatment group (0.84 ng/mL vs. 0.72 ng/mL). The one-sample Wilcoxon signed-rank test results were T = 6.001, p < 0.001 and T = 1.378, p = 0.168, respectively. At the end of follow-up, this treatment did not alter the DRS strata composition ratio (R = 3.06, p = 0.39). The area under the receiver operating characteristic curve for pre-ablation stimulated thyroglobulin (Ps-Tg) predicting non-remission status was 0.64 (95% CI: 0.55-0.73), with the highest Youden index (0.26) at a Ps-Tg cutoff of 20.5 ng/mL, corresponding to a sensitivity of 62.6% and a specificity of 63.3%. For the first suppressed Tg (sup-Tg) predicting non-remission, the AUC was 0.75 (95% CI: 0.67-0.84). The highest Youden index (0.40) was achieved at a sup-Tg cutoff of 1.85 ng/mL, corresponding to a sensitivity of 68.9% and a specificity of 70.8%.
conclusionFor patients with PTC who received
Indexed as
Identifiers
40253651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.